{
  "docId": "019de074-ead2-732b-8415-93449fe93e32",
  "docSlug": "9cc66a7a8f583a45c6978147aa12db97",
  "documentTitle": "Freeman Capital Management | Activist Presentation Deck | 95 slides",
  "authorId": "freeman-capital-management",
  "authorName": "Freeman Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 62,
  "pageCount": 95,
  "prevPage": 61,
  "nextPage": 63,
  "slideType": "propose_solution",
  "function": "propose_solution",
  "density": "balanced",
  "nDataPoints": 12,
  "notes": "The table highlights the optimal dose range for future clinical trials.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ead2-732b-8415-93449fe93e32/62",
  "deckHref": "/decks/019de074-ead2-732b-8415-93449fe93e32",
  "deckJsonHref": "/decks/019de074-ead2-732b-8415-93449fe93e32.json",
  "deckAnchorHref": "/decks/019de074-ead2-732b-8415-93449fe93e32#slide-62",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "paragraph",
      "text": "We believe MindMed should follow the industry gold standard: perform a three-arm Phase III dose finding study.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b0b3b3c-e891-4a1e-bd61-860b2e45cbfc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.5,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "From UHB's studies, we know that 25 µg does not work, 200 µg is effective but not well tolerated, and 100 µg is effective. Thus, there are only two doses to test: 50 µg and 100 µg which can be done in a 3-arm.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "acf19a99-d84c-46da-848a-0b6d25c0266c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "See [4], [11]",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f0a6dd0-78ee-4b65-9ebc-5f01e9639daf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.4,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "table",
      "text": "Dose, Effective, Safety; 25 µg, No, Yes; 50 µg, ?, Yes; 100 µg, Yes, Yes; 200 µg, Yes, Tolerability Issues",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08476eff-5c1f-463e-891a-a655c713f07c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Bringing MM-120 to Market Quickly and Safely",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18b02fd6-b4ce-4e59-80b5-1544b2fdcc76",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 95,
      "from": 61,
      "beatId": "383f2f65-7b68-449f-b311-9bc0591c8aab",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Freeman Capital Management's plan to restore value in Mind Medicine, including bringing MM-120 to market quickly and safely, and aligning G&A and headcount.",
      "position": 2,
      "confidence": 0.9,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 70,
      "from": 62,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "86491bd2-85cc-4539-897c-03a8ac16c31c",
      "evidence": "The document presents Freeman Capital Management's plan to bring MM-120 to market quickly and safely, and to align G&A and headcount.",
      "position": 1,
      "objective": "What are the quick wins and big bets that Freeman Capital Management can make to restore value in Mind Medicine?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}